Marcella Pomeranz
Adult Health · Las Vegas, NVNPI 1174064083
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Johnson & Johnson at 31.5% of the total. 2025 is the largest year on record at $7,641, more than ten times the $606 reported in 2021. Among adult health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Ardelyx, Inc.$3K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$610
- Sanofi$553
- Gilead$416
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$5,47541%
- Food & beverage$7,67757%
- Education$2742%
- Gifts$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 60 | $4,257 |
| Ardelyx, Inc. | 25 | $3,238 |
| AbbVie | 77 | $1,854 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $610 |
| Sanofi | 31 | $553 |
| Gilead | 14 | $416 |
| Pfizer | 17 | $283 |
| Intra-sana Laboratories | 9 | $282 |
| Ironwood Pharmaceuticals, Inc | 10 | $257 |
| Lucid Diagnostics Inc. | 2 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $242 |
| Aimmune Therapeutics, Inc. | 10 | $197 |
| Regeneron Healthcare Solutions, Inc. | 7 | $166 |
| Merck | 9 | $149 |
| Celltrion USA Inc. | 7 | $131 |
| Boston Scientific | 2 | $120 |
| Braintree Laboratories, Inc. | 3 | $108 |
| Redhill Biopharma Inc. | 3 | $64 |
| QOL Medical, LLC | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| Novo Nordisk | 2 | $41 |
| Lilly USA, LLC | 1 | $34 |
| Orphalan Inc | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,506 in reported general payments places this provider in the 95th percentile of 90 adult health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 37 | $95,083 |
| LinzessLinaclotide | 88 | $51,333 |
| ZenpepLipase/Protease/Amylase | 11 | $29,749 |
| IbsrelaTenapanor Hcl | 17 | $26,189 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 31 | $5,046 |
| Lubiprostone | 42 | $5,012 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 314 | $4,648 |
| Sucralfate | 12 | $1,842 |
| Omeprazole | 186 | $1,503 |
| Lactulose | 69 | $1,244 |
| Famotidine | 172 | $982 |
| Pantoprazole Sodium | 121 | $805 |
| Ondansetron OdtOndansetron | 15 | $385 |
| Esomeprazole Magnesium | 20 | $237 |
| Dicyclomine Hcl | 12 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,854 | $146,415125 claims |
| Aimmune Therapeutics, Inc.Zenpep | $197 | $29,74911 claims |
| Ardelyx, Inc.Ibsrela | $3,238 | $26,18917 claims |
| Braintree Laboratories, Inc.Sutab | $108 | $5,04631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 adult health providers in Nevada.
Other adult health in Las Vegas
- Marcia Castro-RosenbergLas Vegas$64K
- Amanda SquiersLas Vegas$36K
- Jasmina FornbacherLas Vegas$14K
- Karisa SonLas Vegas$10K
- Jessica LuceroLas Vegas$6K
- Monica LynamLas Vegas$5K
- Thomas McNeilLas Vegas$5K
- Roger ConantLas Vegas$4K
- Ruth RamirezLas Vegas$4K
- Gener CruzLas Vegas$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.